Revelation Biosciences, Inc. · NASDAQ:REVB

Revelation Biosciences — Investor Presentation (November 2026)

17 slides from Revelation Biosciences's investor presentation, November 2026

  1. Slide 1: Targeting Inflammation, Protecting What Matters: Corporate Presentation

    Targeting Inflammation Protecting What Matters Corporate Presentation NASDAQ: REVB November 2026 www.revbiosciences.com

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These forward-looking statements are generally identified by the w

  3. Slide 3: Why Invest In Revelation Biosciences?

    Why Invest In Revelation Biosciences? Lead drug candidate  Solving a significant unmet need in acute kidney injury (AKI)  AKI: one of medicine’s largest untreated markets  Potential platform for inflammation-driven acute and chronic diseases Value-creating, de-risked development strategy  Phase 2a

  4. Slide 4: Experienced Management

    Experienced Management James Rolke – Chairman of the Board and Chief Executive Officer 30+ years of experience in the biotechnology industry across every phase of drug development, including six INDs and two FDA approvals as Chief Scientific Officer at La Jolla Pharmaceutical Company (acquired by In

  5. Slide 5: Our Programs

    Our Programs PLATFORM PRODUCT INDICATION STATUS DISCOVERY PRE-CLINICAL PHASE 1 PHASE 2 PHASE 31 GEM-AKI Acute Phase 2a launching Intravenous formulation Kidney Injury SIGNIFICANT UNMET NEED GEMINI GEM-CKD Chronic Phase 1 completed SQ formulation Kidney Disease Phase 2 ready Other formulations TBD In

  6. Slide 6: Acute Kidney Injury: Driven by Excess Inflammation

    Acute Kidney Injury: Driven by Excess Inflammation AKI Stats 20% of all hospitalized patients 1 ~50% of ICU patients 1,2 Dialysis is currently the only approved treatment for severe AKI Dialysis results in longer recovery times and significantly higher mortality (>50%)2,3 20-50% develop chronic kidn

  7. Slide 7: Independent Market Research Confirms AKI is a Large Opportunity

    Independent Market Research Confirms AKI is a Large Opportunity Patient Population “This is probably third highest expenditure in the country after oncology and cardiovascular.” Total Hospital Admissions1 @Critical Care Nephrologist 34,426,650 All-Cause AKI Incidence2 6,885,330 “There's not drugs… t

  8. Slide 8: Gemini Activates the TRIF "Dimmer Switch" Pathway to Resolve Inflammation

    Gemini Activates the TRIF “Dimmer Switch” Pathway to Resolve Inflammation Mechanisms of Action  Gemini acts through multiple pathways; other AKI candidates target a single pathway  Gemini breaks the inflammatory cycle by correcting dysregulated healing  Dials down pro-inflammatory cytokines (IL-1

  9. Slide 9: Preclinical: Anti-Inflammatory Effects of Gemini in a UUO Kidney Model

    Preclinical: Anti-Inflammatory Effects of Gemini in a UUO Kidney Model Increased Inflammation-Resolving Cytokines Decreased Scar Tissue-Causing Cytokines Mean IL-10 Increase Mean TGF-β Decrease p < 0.05 p < 0.05 1,000 p < 0.05 1,000 900 900 800 p < 0.05 800 700 700 p < 0.05 TGF-ꞵ (ng/mL) IL-10 (pg/m

  10. Slide 10: Preclinical: Gemini Significantly Reduced Tissue Scarring in UUO Kidney Model

    Preclinical: Gemini Significantly Reduced Tissue Scarring in UUO Kidney Model Mean Collagen Deposition (Scar Tissue Formation) p < 0.05 p < 0.05 From Inflammation to Scarring 5%  Uncontrolled scarring gradually replaces functional kidney tissue, resulting in loss Collagen Fraction Volume 4% of func

  11. Slide 11: Phase 1: Gemini Was Biologically Active and Safe in Healthy Volunteers

    Phase 1: Gemini Was Biologically Active and Safe in Healthy Volunteers1 Gemini administration produced the anti-inflammatory cytokines (IL-10 and IL-1RA) consistent with the expected mechanism of action Mean IL-10 Peak Increase Mean IL-1RA Peak Increase 25 p < 0.0001 60,000 p < 0.0001 50,000 20 p <

  12. Slide 12: Phase 1b: Gemini Safely Rebalanced Immune Function in Patients with CKD

    Phase 1b: Gemini Safely Rebalanced Immune Function in Patients with Chronic Kidney Disease1,2 Gemini Significantly and Durably Gemini Significantly and Durably Restored Immune Reduces inflammation Responsiveness (Correcting Immunoparalysis) AUC: p < 0.0001 AUC: p < 0.0002 125% 125% Degree of Respons

  13. Slide 13: AKI Scientific Advisory Board

    AKI Scientific Advisory Board Laurence Busse, MD, MBA, FCCM Lead Principal Investigator Critical Care Nephrologist; Medical Director for critical care at Emory Johns Creek Hospital. Javier Neyra, MD, MSCS Principal Investigator Critical Care Nephrologist; Professor of Sean Bagshaw, MD, MSc, FRCPC Me

  14. Slide 14: Near-Term Value-Driving Phase 2a Safety and Efficacy Study in AKI

    Near-Term Value-Driving Phase 2a Safety and Efficacy Study in AKI1 GEMINI – Daily IV Push x 5 Days Randomization Evaluations of Safety and Screening 1:1 Efficacy Placebo – Daily IV Push x 5 Days Advantages:  Short timeline to data (~1 year vs. 2+ years)  Efficacy to include evaluation of clinically

  15. Slide 15: Financial Overview

    Financial Overview Key Financial Summary 9/30/2026 Beneficial Holders Shares % Cash $9,121,630 Management 107,071 15.6 Stockholders Equity $7,233,702 Total 107,071 15.6 Cash Used for Operations $8,133,206 Cash Provided by Financing $6,666,012 Cap Table Shares Common Stock 683,442 Common Stock Warran

  16. Slide 16: Potential Future Applications Using Gemini – A Platform Opportunity

    Potential Future Applications Using Gemini – A Platform Opportunity Neurodegenerative Diseases • Parkinson's • Alzheimer's Disease Cardiovascular Disease • Myocarditis • Pericarditis Hepatic Disease • Cardiorenal Syndrome • MASH • Secondary IgA Nephropathy Renal Disease • Chronic Kidney Disease • Ig

  17. Slide 17: Thank You!

    Thank You! For more information, please visit www.revbiosciences.com 17

Revelation Biosciences — Investor Presentation (November 2026) on 6ix